Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas

NCT02271945 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

10

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed/Refractory Aggressive B-cell Lymphomas

Interventions

DRUG: MEDI-551 12 mg/kg
DRUG: MEDI0680 2.5 mg/kg
DRUG: MEDI0680 10 mg/kg

Sponsor

MedImmune LLC